1-9 of 9
Anderson J. Ryan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Tina Cascone, Li Xu, Heather Y. Lin, Wenbin Liu, Hai T. Tran, Yuan Liu, Kathryn Howells, Vincent Haddad, Emer Hanrahan, Monique B. Nilsson, Maria A. Cortez, Uma Giri, Humam Kadara, Babita Saigal, Yun-Yong Park, Weiyi Peng, Ju-Seog Lee, Anderson J. Ryan, Juliane M. Jüergensmeier, Roy S. Herbst, Jing Wang, Robert R. Langley, Ignacio I. Wistuba, Jack J. Lee, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5489–5501.
https://doi.org/10.1158/1078-0432.CCR-16-3216
Published: 14 September 2017
View article titled, The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Open the PDF for The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity

Vijaya L. Damaraju, Tara Scriver, Delores Mowles, Michelle Kuzma, Anderson J. Ryan, Carol E. Cass, Michael B. Sawyer
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 176–186.
https://doi.org/10.1158/1078-0432.CCR-13-2293
Published: 05 January 2014
View article titled, Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
Open the PDF for Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity in another window
Journal Articles

Reply

Emer O. Hanrahan, Anderson J. Ryan, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1341.
https://doi.org/10.1158/1078-0432.CCR-09-2452
Published: 15 February 2010
View article titled, Reply
Open the PDF for Reply in another window
Journal Articles

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Emer O. Hanrahan, Anderson J. Ryan, Helen Mann, Sarah J. Kennedy, Peter Langmuir, Ronald B. Natale, Roy S. Herbst, Bruce E. Johnson, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3600–3609.
https://doi.org/10.1158/1078-0432.CCR-08-2568
Published: 18 May 2009
View article titled, Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer
Open the PDF for Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model

Sungweon Choi, Daisuke Sano, Melvina Cheung, Mei Zhao, Samar A. Jasser, Anderson J. Ryan, Li Mao, Wan-Tao Chen, Adel K. El-Naggar, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5081–5089.
https://doi.org/10.1158/1078-0432.CCR-08-0245
Published: 12 August 2008
View article titled, Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model
Open the PDF for Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model in another window
Journal Articles

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

Jeremy N. Rich, Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, Michael W. Graner, B.K. Ahmed Rasheed, Ling Wang, David A. Reardon, Anderson J. Ryan, Catherine Wheeler, Isaiah Dimery, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8145–8157.
https://doi.org/10.1158/1078-0432.CCR-05-0319
Published: 18 November 2005
View article titled, ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Open the PDF for ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors in another window
Journal Articles

Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies

Giulia Taraboletti, Gianluca Micheletti, Romina Dossi, Patrizia Borsotti, Michele Martinelli, Fabio Fiordaliso, Anderson J. Ryan, Raffaella Giavazzi
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (7): 2720–2726.
https://doi.org/10.1158/1078-0432.CCR-04-1616
Published: 06 April 2005
View article titled, Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies
Open the PDF for Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies in another window
Journal Articles

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Jeffrey L. Evelhoch, Patricia M. LoRusso, Zhanquan He, Zachary DelProposto, Lisa Polin, Thomas H. Corbett, Peter Langmuir, Catherine Wheeler, Andrew Stone, Joanna Leadbetter, Anderson J. Ryan, David C. Blakey, John C. Waterton
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3650–3657.
https://doi.org/10.1158/1078-0432.CCR-03-0417
Published: 01 June 2004
View article titled, Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
Open the PDF for Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 in another window
Journal Articles

Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models

David C. Blakey, F. Russell Westwood, Mike Walker, Gareth D. Hughes, Peter D. Davis, Sue E. Ashton, Anderson J. Ryan
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (6): 1974–1983.
Published: 01 June 2002
View article titled, Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models
Open the PDF for Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models in another window